ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2227

Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels?

Carolina Tornero1, Victoria Navarro-Compán 2, Jair Antonio Tenorio 3, Sara García 4, Antonio Buño 5, Irene Monjo 6, Chamaida Plasencia 7, Jose María Iturzaeta 8, Pablo Lapunzina 3, Karen Heath 3, Alejandro Balsa 7 and Pilar Aguado 1, 1Rheumatology Department. La Paz University Hospital., Madrid, 2University Hospital La Paz, IdiPaz, Madrid, Spain, 3Genetics Department. La Paz University Hospital. CIBERER, Madrid, 4Rheumatology Department. La Paz University Hospital, Madrid, 5Clinical Biochemistry, La Paz University Hospital, Madrid, 6FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, 7Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, 8Clinical Biochemisty. La Paz University Hospital, Madrid

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: alkaline phosphatase, Hypophosphatasemia and Metabolic bone diseases, hypophosphatasia

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Hypophosphatasia (HPP) is caused by mutations in ALPL, resulting in low alkaline phosphatase (ALP) levels. The determination of ALPL mutation may not be accessible in clinical practice. In this case, an alternative simple method to predict the presence or absence of the mutation would be very useful. This study aimed to characterize the main clinical and laboratory features associated with the presence (HPP + GT) or absence (HPP – GT) of mutations in the ALPL gene among subjects with persistently low ALP levels.

Methods: During this cross-sectional study, the laboratory reports from 386,353 people attending a Tertiary University Hospital from 2009 to 2015 were screened. 109 adult subjects with persistently low ALP values (≥2 measurements below or equal to 35 IU/L and none above 45 IU/L) were enrolled and 85 gave their consent for genetic testing. During one visit, a systematized questionnaire was performed to retrieve demographic, clinical and laboratory data and a genetic test to detect HPP was performed. Comparisons between groups were performed using the Student’s t-test for unpaired data, if normally distributed; or Mann-Whitney U test, if not normally distributed. Logistic regression models adjusted for confounders were employed to investigate the association between clinical and laboratory characteristics and the presence/absence or ALPL mutation.

Results: Forty-seven percent (40/85) of subjects showed mutations in ALPL: 75% (30/40) were heterozygous for a pathogenic variant, 17.5% (7/40) for a likely pathogenic variant, 5% (2/40) for a variant of unknown significance (VUS) and one patient diagnosed of infantile HPP harbored compound heterozygous mutations. Demographic characteristics are shown in table 1. The presence of mutation was significantly associated with the presence of musculoskeletal pain (OR: 5.9; 95% IC: 1.7-20.5) and orthopedic surgery (OR: 4.8; 95% IC: 0.7-33.3). Metatarsal stress fractures were also more frequent in the HPP + GT group (4 vs 0, p=0.007). In terms of laboratory paramethers, ALP levels were lower in the HPP + GT group compared with HPP –GT group (24.2 vs 29.1 IU/L, p < 0.0001; respectively). Interestingly, levels below 25 UI/L showed a specificity of 97.8% and a positive predictive value of 94.4% to detect a positive genetic test.

Conclusion: In our cohort, ALP levels below 25 IU/L were identified as a very good predictor for the presence of mutations in ALPL. Furthermore, the presence of musculoskeletal pain and previous orthopedic surgery were also associated to a positive genetic test.


Disclosure: C. Tornero, None; V. Navarro-Compán, AbbVie, 5, 8, Bristol, 8, Bristol, Roche, 8, Eli Lilly and Company, 5, 8, Eli Lilly, Novartis, Abbvie, UCB, MSD, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, Roche, 8, UCB, 5, 8; J. Tenorio, None; S. García, None; A. Buño, None; I. Monjo, BMS, 2; C. Plasencia, None; J. Iturzaeta, None; P. Lapunzina, None; K. Heath, None; A. Balsa, BMS, 2, Roche Pharma, 2; P. Aguado, None.

To cite this abstract in AMA style:

Tornero C, Navarro-Compán V, Tenorio J, García S, Buño A, Monjo I, Plasencia C, Iturzaeta J, Lapunzina P, Heath K, Balsa A, Aguado P. Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/can-we-predict-hypophosphatasia-mutation-result-based-on-alkaline-phosphatase-serum-levels/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-we-predict-hypophosphatasia-mutation-result-based-on-alkaline-phosphatase-serum-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology